What is the clinical evidence from this study?

Study design: Editorial. Population: Perioperative Left Ventricular Dysfunction. Intervention: Levosimendan vs. Milrinone or other inotropes.

What question did this study set out to answer?

To evaluate the pharmacological mechanisms and clinical utility of levosimendan compared with traditional inodilators for managing perioperative left ventricular dysfunction in cardiac surgery.

March 15, 2007Anesthesia & Analgesia

Levosimendan in Cardiac Surgery: A Unique Drug for the Treatment of Perioperative Left Ventricular Dysfunction or Just Another Inodilator Searching for a Clinical Application?

View Full Paper

Ask AI

Bookmark

Key result

Levosimendan offers theoretical advantages for treating perioperative left ventricular dysfunction, but whether these translate into improved clinical outcomes compared to established inotropes remains unknown.

Why the study?

Does the combination of levosimendan and dobutamine improve hemodynamics and reduce the need for prolonged inotropic and mechanical support compared to milrinone and dobutamine in patients with severe LV dysfunction undergoing cardiac surgery?

Population

Patients with preoperative left ventricular dysfunction undergoing cardiac surgery who required inotropic…

Comparison

Combination of IV infusions of levosimendan and… vs Combination of IV infusions of milrinone and…

Design

Editorial

Follow-up

48 hours

Authors

PPPaul S. PagelStructural Heart Disease

Discussion

Member takes

Implication

Levosimendan combined with dobutamine may provide superior hemodynamic benefits and reduce the duration of required support compared to milrinone-dobutamine in cardiac surgery patients with severe preoperative LV dysfunction.

Key Points

To evaluate the pharmacological mechanisms and clinical utility of levosimendan compared with traditional inodilators for managing perioperative left ventricular dysfunction in cardiac surgery.
Synthesized mechanistic and clinical evidence on calcium sensitizers, comparing levosimendan's inotropic, vasodilatory, and anti-ischemic properties to beta-agonists and PDE III inhibitors.
Evaluated clinical trials, emphasizing a randomized study comparing levosimendan plus dobutamine against milrinone plus dobutamine in 30 cardiac surgery patients with ejection fraction <30%.
Levosimendan stabilizes calcium-bound troponin C and opens KATP channels, augmenting contractility and vasodilation without raising intracellular calcium or oxygen demand.
In cardiac surgical patients (n=15 per arm), levosimendan-dobutamine augmented stroke volume index to a greater degree at 12 and 24 hours post-bypass than milrinone-dobutamine.
Levosimendan-treated patients required significantly lower cumulative doses of dobutamine and norepinephrine, shorter durations of inotropic therapy and mechanical circulatory support, and had faster extubation times.

Structured PICO

Population

Patients with preoperative left ventricular dysfunction (ejection fraction <30%) undergoing cardiac surgery who required inotropic support after cardiopulmonary bypass (n=30, 15 per group)

Intervention

Combination of IV infusions of levosimendan (0.1 μg/kg/min) and dobutamine (5 μg/kg/min)

Comparator

Combination of IV infusions of milrinone (0.5 μg/kg/min) and dobutamine

Outcome

Cardiovascular effects during the first 24 h after cardiopulmonary bypass, total doses of dobutamine and norepinephrine required during the first 48 h, duration of inotropic drug treatment, duration of mechanical circulatory support, and time to tracheal extubationsurrogate

Limitations

Whether the theoretical advantages of levosimendan will ultimately translate into improved outcome in cardiac surgical patients with LV dysfunction is unknown and requires additional investigation.

Cite This Study

Paul S. Pagel (2007) conducted an editorial in Perioperative Left Ventricular Dysfunction. Levosimendan vs. Milrinone or other inotropes was evaluated. Levosimendan offers theoretical advantages for treating perioperative left ventricular dysfunction, but whether these translate into improved clinical outcomes compared to established inotropes remains unknown.

synapsesocial.com/papers/6a94772f374ec050522dd114 https://doi.org/10.1213/01.ane.0000256864.75206.6d

View Full Paper

Ask AI

Bookmark

Levosimendan in Cardiac Surgery: A Unique Drug for the Treatment of Perioperative Left Ventricular Dysfunction or Just Another Inodilator Searching for a Clinical Application?

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Levosimendan in Cardiac Surgery: A Unique Drug for the Treatment of Perioperative Left Ventricular Dysfunction or Just Another Inodilator Searching for a Clinical Application?

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider